Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Question to the board

Perhaps it is just the pps decline that has me thinking about whether DP and BOD have the right stuff.  Some of the reasons I say this.

1. Susequest to the firt two dividends, DP indicated that further dividends were possible.  I assume the reasons for the first two were to get warrent holders to convert, although I do not believe they were portrayed that way. Why mention possibility of further dividends when not a good idea, then no follow through on further dividend. Could not have helped the pps.

2. Talk of a purchase. With what? And until they can figure out a way to get the pps ship turned around totally rediculous. The thought of many millions of shares being sold at some extreme discount can not be helping the pps.

The Dutton report and the PR firm are good ideas if/when they are able to get the pps going in the other direction.  Total waste of money here and probably did more to hurt pps than help it. 

My hope is that the ineptness is only a ploy to buy back cheap shares, but that seems like a stretch. Would appreciate input from those that know DP an BOD. Enough to worry about w/o having to worry about mgt's capability.  TIA for any responses.  

Share
New Message
Please login to post a reply